Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases
Version of Record online: 26 APR 2011
Copyright © 2011 Wiley Periodicals, Inc.
Head & Neck
Volume 35, Issue 1, pages E6–E10, January 2013
How to Cite
Lee, J.-J., Cheng, S.-J., Wang, Y.-P., Jeng, J.-H., Chiang, C.-P. and Kok, S.-H. (2013), Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases. Head Neck, 35: E6–E10. doi: 10.1002/hed.21758
- Issue online: 15 DEC 2012
- Version of Record online: 26 APR 2011
- Manuscript Accepted: 24 JAN 2011
- yearly zoledronic acid;
- tooth extraction;
- dental implantation;
Once-yearly zoledronic acid has been proven effective in the management of osteoporosis. Osteonecrosis of the jaws (ONJ) related to its use has not been reported since its approval in 2007.
Two women with osteoporosis/osteopenia developed ONJ after the second infusion of yearly zoledronic acid. They had no other systemic diseases and ONJ occurred after oral surgeries, which were performed about 2 months following drug administration.
In 1 case osteonecrosis of the maxilla resolved after conservative therapy and sequestrectomy. In the other case bone necrosis developed on both sides of mandible, and the symptoms/signs of ONJ were partially responsive to conservative treatment.
ONJ related to yearly zoledronic acid is a severe complication that should not be ignored. To minimize the risk, we recommend preventive oral care before the start of therapy and avoiding dental invasive procedures within 3 months after drug administration. © 2011 Wiley Periodicals, Inc. Head Neck, 2013